Disis ML - Search Results

1

Clinical studies of vaccines targeting breast cancer.

Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. Ko BK, et al. Among authors: disis ml. Clin Cancer Res. 2003 Aug 15;9(9):3222-34. Clin Cancer Res. 2003. PMID: 12960107 Review.

2

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

Disis ML, Cheever MA. Disis ML, et al. Adv Cancer Res. 1997;71:343-71. doi: 10.1016/s0065-230x(08)60103-7. Adv Cancer Res. 1997. PMID: 9111870 Review.

3

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

Disis ML, Grabstein KH, Sleath PR, Cheever MA. Disis ML, et al. Clin Cancer Res. 1999 Jun;5(6):1289-97. Clin Cancer Res. 1999. PMID: 10389911 Clinical Trial.

4

Immunotherapeutic approaches for the treatment of breast cancer.

Knutson KL, Schiffman K, Rinn K, Disis ML. Knutson KL, et al. Among authors: disis ml. J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):353-65. doi: 10.1023/a:1018714300217. J Mammary Gland Biol Neoplasia. 1999. PMID: 10705919 Review.

5

Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.

Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Disis ML, et al. Clin Cancer Res. 2000 Apr;6(4):1347-50. Clin Cancer Res. 2000. PMID: 10778962

6

Cancer vaccines targeting the HER2/neu oncogenic protein.

Disis ML, Schiffman K. Disis ML, et al. Semin Oncol. 2001 Dec;28(6 Suppl 18):12-20. Semin Oncol. 2001. PMID: 11774201 Review.

7

Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

Knutson KL, Schiffman K, Cheever MA, Disis ML. Knutson KL, et al. Among authors: disis ml. Clin Cancer Res. 2002 May;8(5):1014-8. Clin Cancer Res. 2002. PMID: 12006513 Clinical Trial.

8

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Disis ML, et al. J Clin Oncol. 2002 Jun 1;20(11):2624-32. doi: 10.1200/JCO.2002.06.171. J Clin Oncol. 2002. PMID: 12039923 Clinical Trial.

9

Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.

Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. Salazar LG, et al. Among authors: disis ml. Clin Cancer Res. 2003 Nov 15;9(15):5559-65. Clin Cancer Res. 2003. PMID: 14654536 Clinical Trial.

10

Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice.

Knutson KL, Almand B, Dang Y, Disis ML. Knutson KL, et al. Among authors: disis ml. Cancer Res. 2004 Feb 1;64(3):1146-51. doi: 10.1158/0008-5472.can-03-0173. Cancer Res. 2004. PMID: 14871850

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters